Boston Scientific Corp. got a boost from Leerink Swann analyst Rick Wise, who upgraded his rating for the Natick, Mass.-based medical devices giant to “outperform.”
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Abbott extends Xience V trial
Abbott Vascular extended its post-approval study of the Xience V (PDF) drug-eluting stent, making as many as 2,000 patients in the trial eligible for another study of dual anti-platelet therapy.
The Abbott Park, Ill.-based devices giant said the expansion of the study examining its everolimus-eluting coronary stent opens up the Dual Anti-Platelet Therapy (PDF) trial to more than 2,000 potential subjects.
Federal judge to Cordis Corp.: My bad
A federal judge apologized to both parties and the federal bench in overturning a prior, erroneous ruling that a pair of Johnson & Johnson unit Cordis Corp.’s stent patents were unenforceable.
Judge Susan Robinson of the U.S. District Court for the District of Delaware said her 2002 decision in Cordis Corp. v. Boston Scientific Corp. et al. was wrong and reversed the opinion, setting the stage for yet another round in the more than 10-year-old case.
Angiotech: Taxus stent sales still slow, but improving
Sales of Boston Scientific Corp.’s Taxus coronary stent remain well off last year’s pace and have declined significantly over the past two years due to increased competition, according to regulatory filings (PDF) by the Vancouver-based pharmaceutical company that makes the drug used in the stent’s coating.
Medtronic to pay $442 million to settle Abbott Labs stents patent battle
The bad news just keeps on coming for Medtronic Inc., the Minneapolis-based medical device giant.
UPDATE: Boston Scientific plows ahead despite lawsuit
What a difference a day makes.
Yesterday Boston Scientific Corp. was fielding false claims and Medicare fraud charges.
Today the Natick, Mass.-based medical devices leviathan got word of a possible debt rating upgrade and said the Food & Drug Administration gave pre-market approval to its Taxus Liberté long stent.
Boston Scientific announces $128 million Irish R&D lab
Boston Scientific Corp. announced plans for a $128 million research & development lab in Galway, Ireland.
The Natick device maker, which already employs about 5,000 in Ireland, said the project will create roughly 45 jobs over five years, the Independent reported. The lab will focus on early-stage development projects.
CorNova lands CE Mark for coronary stent
CorNova Inc.‘s Valecor platinum coronary stent system won CE mark approval for sale in the European Union.
The Burlington-based device maker said the next-generation bare-metal device, made of cobalt-chromium using ion-based Nanofusion technology, presents a pure platinum surface to both the lumen and artery wall to protect them from the less-compatible elements inherent in medical-grade alloys.
The company is also developing balloon catheters designed to measure blood vessels from within the balloon during procedures.
Abbott Labs lands CE Mark for Xience Prime stent
Abbott Laboratories fired the latest salvo in the long-running stent war, saying it plans to begin selling its Xience Prime coronary device in Europe during the third quarter after winning CE Mark approval from the European Union.
The latest version of the Chicago-based medical device monolith’s drug-eluting Xience platform competes head-to-head with products from Natick-based peer Boston Scientific, Johnson & Johnson and Medtronic Inc.
FDA approves Boston Scientific’s Taxus Liberté Atom stent
The Food & Drug Administration gave the nod to Boston Scientific Corp.‘s small-vessel paclitaxel-eluting stent, the Taxus Liberté Atom, clearing the way for it to hit the market next month.
The federal watchdog agency cleared the device for treatment of coronary vessels as small as 2.25mm in diameter, making it and its Taxus Express Atom cousin the only two drug-eluting stents approved for procedures involving small vessels in the United States.
Boston Scientific begins Epic stent trial in U.S. as J&J fires another salvo in the stent wars
Boston Scientific Corp. started its first U.S. human trials of its Epic peripheral stent, even as rival Johnson & Johnson fired off another salvo in the stent wars.
The Natick-based stents giant is calling its new nickel-titanium alloy stent, designed to treat iliac artery disease, the “next generation” of nitinol device. The stent launched in Europe in April.